Nine Masts Capital’s AstraZeneca AZN Stock Holding History

Nine Masts Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-92	Closed	-$13K	–	257
2017 Q4	$13K	Buy	+92	New	+$6.2K	﹤0.01%	206

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nine Masts Capital's AZN Position: Q2 2026 in Review

Nine Masts Capital sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 2,000 shares — an estimated $394K sold.

Nine Masts Capital first reported a position in AZN in Q1 2026 and held it in 1 quarter. The position peaked at $394K in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Nine Masts Capital reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
Nine Masts Capital sold 2,000 AstraZeneca shares in Q2 2026, an estimated $394K.
Nine Masts Capital first reported a position in AstraZeneca in Q1 2026 and held it in 1 quarter.
Nine Masts Capital's AstraZeneca position peaked at $394K in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.